Calibre What Science Can Do

This website contains promotional content about AstraZeneca Medications. This website is intended for healthcare professionals involved in the Acute Coronary Syndrome care pathway, such as hospital specialists from cardiology and cardiology-related departments, including A&E and elderly care, as well as GPs with a specific interest in cardiology, nurses, pharmacists and payers with budget responsibilities in cardiology.

ACS insights

January 2018 - New!

The why, when and how of antiplatelet therapy in high-risk, post-myocardial infarction patients
Professor Christopher Gale

Professor Christopher Gale

Professor Christopher Gale is a professor of cardiovascular medicine at the Division of Epidemiology, University of Leeds. He is also an honorary consultant cardiologist and leads the Medical Research Council (MRC) Bioinformatics Centre’s Cardiovascular Epidemiology group. 

Professor Gale qualified in medicine at the London Hospital Medical College and obtained a BSc (Hons) in psychology. After working as a junior doctor at the Royal London Hospital andbecoming a member of the Royal College of Physicians, he became a MRC clinical training fellow and undertook a PhD in molecular biology at the University of Leeds. Professor Gale undertook specialty training in cardiology at the Leeds General Infirmary, where he was a NIHR academic clinical lecturer. He holds a Master’s in clinical education and a Master’s in statistical epidemiology. As a consultant cardiologist, he completed a 5-year NIHR Clinician Scientist Award to become an NIHR clinical trials fellow.

Professor Gale has published over 100 original research papers and is Deputy Editor of European Heart Journal – Quality of Care and Clinical Outcomes. Professor Gale is Chair of the research committee of the National Institute for Cardiovascular Outcomes Research. In addition to membership of the National Institute for Health and Care Excellence Indicator Advisory Committee, he is an oversight committee member of the European Society of Cardiology (ESC) EURObservational Research Programme and Secretary of the ESC Acute Cardiovascular Care Association.

The why, when and how of antiplatelet therapy in high-risk, post-myocardial infarction patients
Professor Philippe Gabriel Steg

Professor Philippe Gabriel Steg

Dr Philippe Gabriel Steg is a professor of cardiology at Université Paris Diderot and the National Heart and Lung Institute of Imperial College London. He is also an interventional cardiologist and Chief of the Cardiology Department at Hôpital Bichat, Assistance Publique-Hôpitaux de Paris. 

Dr Steg participates in the leadership of many trials in coronary artery disease and is currently Chair/co-Chair or principal investigator of several large clinical trials or registries such as ODYSSEY Outcomes, CLARIFY, THEMIS, REALITY, and SCORED. He is Chair of the FACT: French Alliance for Cardiovascular Clinical Trials academic research network, was co-Chair of the REACH registry and the GRACE registry publication committee, and participated in numerous data monitoring committees or clinical events committees.

Dr Steg is co-Coordinator of the Département Hospitalo-Universitaire FIRE affiliated with INSERM, Université Paris Diderot and Assistance Publique – Hôpitaux de Paris, and Coordinator of the iVASC research consortium. He has authored over 1,000 articles in international peer-reviewed journals, is Associate Editor for Circulation and on the editorial board for the European Heart Journal. He received the silver medal of the European Society of Cardiology (ESC) in 2011 and co-chaired the ESC task force in charge of the 2012 Guidelines for management of ST-segment elevation myocardial infarction.

October 2017

Recognition of the ongoing ischaemic risk our patients face
Prof Johanne Silvain

Johanne Silvain

Dr Johanne Silvain is a Professor of Medicine at the University of Pierre and Marie Curie in Paris, France. He is an interventional cardiologist, with expertise in coronary angioplasty and CTO and is the Director of the Coronary Intensive Care Unit. He qualified at the University of Medicine of Paris (UPMC) and has authored over 100 publications in established and respected journals. Dr Silvain’s research interests lie in the area of thrombosis (thrombotic composition) to antithrombotic (anticoagulant and antiplatelet agents) and its consequences on bleeding and transfusion.

Individualised patient approaches for DAPT; duration to 12 months
Dr Christopher Granger

Dr Christopher Granger

Dr. Granger, MD is a Professor of Medicine in the Division of Cardiology and a member of the Duke Clinical Research Institute, Duke University School of Medicine in North Carolina, USA. Dr. Granger is a Fellow of the American College of Cardiology, the American Heart Association and of the European Society of Cardiology. His primary research interests are in the conduct and methodology of large randomized trials in heart disease. He is Associate Editor of the American Heart Journal and serves on the editorial board of the Journal of American College of Cardiology.

Individualised patient approaches for DAPT; duration beyond 12 months
Dominick Angiolillo

Dr Dominick Angiolillo

Dr. Angiolillo joined the University of Florida College of Medicine – Jacksonville in 2004. Currently, Dr. Angiolillo is a Professor of Medicine with tenure status. He is also the Director of Cardiovascular Research, Program Director of the Interventional Cardiology Fellowship Program and a Staff Cardiologist and Interventional Cardiologist with the University of Florida Health System. Dr. Angiolillo is board certified by the American Board of Internal Medicine in internal medicine, cardiovascular disease and interventional cardiology.

May 2017

Dual antiplatelet therapy: Identifying high-risk and individualising care in patients one year after an ACS event
Azfar Zaman and Stephen Wheatcroft

Azfar Zaman

Azfar Zaman is a professor of clinical cardiology at Freeman Hospital and Newcastle University, Newcastle upon Tyne and Head of Coronary Intervention and Director of the cardiac catheter laboratories at Freeman Hospital. He completed his postgraduate training in cardiology at regional centres in Leeds, London and Cardiff, following which, he was awarded a Fulbright Scholarship and a 2-year British Heart Foundation International Fellowship to study vascular biology at Mount Sinai Medical Center, New York.

As Clinical Director for Cardiovascular Research, and with interests in clinical research, atherothrombosis in diabetes and clinical trials, Professor Zaman has been awarded research grants from the British Heart Foundation, Diabetes Wellness Research Foundation and the National Institute for Health Research. He currently leads a team of 16 individuals conducting clinical trials and research in cardiology and has built an impressive publication record with over 100 peer-reviewed publications.

Stephen Wheatcroft

Dr Stephen Wheatcroft is a senior lecturer in cardiovascular medicine at the Division of Cardiovascular and Diabetes Research, University of Leeds, and Consultant Interventional Cardiologist at Leeds General Infirmary. He divides his time between supervising a research team, focusing on understanding the molecular basis of cardiovascular disease in diabetes, clinical commitments in general cardiology and percutaneous coronary intervention.

Dr Wheatcroft qualified in medicine at the University of Birmingham, and after general medical training in the West Midlands, he undertook speciality training in cardiology in the South East of England. Here, he was based at King’s College Hospital, London, where he developed a strong interest in vascular biology after completing a PhD with Mark Kearney and Ajay Shah. This then lead to him undertaking a visiting post-doctoral fellowship with Professor Juan Badimon in New York.

After moving to Leeds, Dr Wheatcroft secured a British Heart Foundation Intermediate Fellowship and was awarded a European Research Council Fellowship. In this position, he investigated the vascular biology of the insulin-like growth factor binding protein axis. He currently sits on the committees of the British Atherosclerosis Society, Heart Research UK and the British Heart Foundation Project Grants Committee and has authored over 80 peer reviewed publications.

Dual antiplatelet therapy: Identifying high-risk and individualising care in patients one year after an ACS event
Azfar Zaman and Gilles Montalescot

Azfar Zaman

Azfar Zaman is a professor of clinical cardiology at Freeman Hospital and Newcastle University, Newcastle upon Tyne and Head of Coronary Intervention and Director of the cardiac catheter laboratories at Freeman Hospital. He completed his postgraduate training in cardiology at regional centres in Leeds, London and Cardiff, following which, he was awarded a Fulbright Scholarship and a 2-year British Heart Foundation International Fellowship to study vascular biology at Mount Sinai Medical Center, New York.

As Clinical Director for Cardiovascular Research, and with interests in clinical research, atherothrombosis in diabetes and clinical trials, Professor Zaman has been awarded research grants from the British Heart Foundation, Diabetes Wellness Research Foundation and the National Institute for Health Research. He currently leads a team of 16 individuals conducting clinical trials and research in cardiology and has built an impressive publication record with over 100 peer-reviewed publications.

Gilles Montalescot

Gilles Montalescot is a professor of cardiology at the Pitié-Salpêtrière Hospital in Paris, France, where he heads the Department of Cardiology at the Institute of Cardiology. He is a practicing interventional cardiologist and has extensive experience in basic and clinical research. Dr Montalescot is Director of the INSERM research unit UMRS_1166 on thrombosis and Chairman of the ACTION study group, an academic research organisation based at Pitié-Salpêtrière Hospital in Paris. He has served on several task force committees on antithrombotic drugs and acute coronary syndromes and is the current Chairman of the Stable Coronary Artery Disease guidelines of the European Society of Cardiology. 

Dr Montalescot has received several awards in his country including the J. Valade prize from the Fondation de France and the J. Escalle award from the National Academy of Medicine. Dr Montalescot is a member of several editorial boards and has published over 400 peer-reviewed original articles in journals such as NEJM, JAMA, Lancet and Circulation. Internationally, Dr Montalescot has also been an invited plenary session speaker at all the major congresses such as the European Society of Cardiology, the American college of Cardiology and the American Heart Association.